Home 1. Company (Purpose, Team, Partners) 2. About Us (Vision, DFU, Market) 3. Our Science (Mechanism) 4. Product Pipeline (Indications) Videos & Media Gallery 5. News & Blog (Press, Publications & Insights)
R&D & Clinical Strategy

Advancing a High-Value
Therapeutic Pipeline.

Structured preclinical validation advancing Zegen-X5 toward IND-enabling studies and strategic biopharmaceutical partnership milestones.

Asset Portfolio

Development Programs & Clinical Stages

Four targeted indications addressing acute, chronic, and emergency wound-healing deficits using tailored delivery modalities.

ZGX-5 Zegen-X5 Preclinical Stage

Diabetic Foot Ulcers (DFU)

Delivery Modality: Topical Gel

Target Milestone
Preclinical Efficacy, GLP Toxicology & IND-Enabling Studies

Targeted lead preclinical candidate for stalled chronic neuropathic and neuroischemic diabetic foot ulcers. Demonstrates 2X acceleration in closure rate at Day 10 in preclinical models.

Stage: Preclinical 30%
Discovery Preclinical IND-Enabling Phase I Phase II+
ZGX-102 Zegen-X5 Active Preclinical

Venous Leg Ulcers (VLU)

Delivery Modality: Matrix Sheet

Target Milestone
Ex-vivo human skin barrier restoration assay completion

Designed to work synergistically under multi-layer compression wraps for chronic venous insufficiency wounds.

Stage: Preclinical Optimization 25%
Discovery Preclinical IND-Enabling Phase I Phase II+
ZGX-103 Zegen-X5 Preclinical Validation

Deep Partial-Thickness Burns & Trauma

Delivery Modality: Topical Spray

Target Milestone
Porcine thermal burn model readout & BARDA engagement

Rapid field deployment candidate for thermal burn debridement and trauma wound triage without requiring cold chain logistics.

Stage: Preclinical Validation 25%
Discovery Preclinical IND-Enabling Phase I Phase II+
ZGX-104 Zegen-X5 Lead Optimization

Surgical Incision Dehiscence & High-Tension Closures

Delivery Modality: Extended-Release Candidate

Target Milestone
Biocompatible polymer pharmacokinetic characterization

Designed to enhance tissue tensile strength and prevent surgical breakdown in high-risk incisions.

Stage: Discovery & Lead Optimization 15%
Discovery Preclinical IND-Enabling Phase I Phase II+
Financing & Execution Plan

Capital Efficiency & Targeted Use of Funds

Structured to maximize value inflection points across preclinical validation and IND-enabling milestones.

55%

DFU Preclinical & IND-Enabling

Completion of lead DFU preclinical efficacy, toxicology validation, and FDA IND-enabling studies.

20%

Formulation & CMC Scale-Up

Porcine GLP safety validation and commercial-grade cGMP batch manufacturing readiness.

15%

Pipeline Indication Expansion

Preclinical validation across expanded chronic ulcer and thermal burn indications.

10%

Regulatory & G&A

Legal, patent prosecution, regulatory preparation, and general operating costs.

Partner With ZegeneX

Explore co-development collaborations, territory licensing rights, and institutional investment opportunities in our lead and pipeline assets.

Request Partnering Package & Data Room Access
Partner With Us

Help write the next chapter of wound care.

We work with strategic biopharma partners, foundation grants, and visionary investors who share our conviction that healing should be universal — not constrained by infrastructure, refrigeration, or geography.